Project Grant HT9425261E267
Award Date 7/1/26
Completion Date 6/30/29
Dollars Obligated $1.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded Sloan-Kettering Institute for Cancer Research a $604,902 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2026 through June 30, 2029. The award supports research titled "Modeling and Targeting FH-Deficient Renal Cell Carcinoma for Precision Therapy," which focuses on developing precision medicine approaches for a specific subtype of kidney cancer. The research...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $352,000 under the Military Medical Research and Development program (CFDA 12.420) to the Sloan-Kettering Institute for Cancer Research for the project period September 1, 2025, through August 31, 2027. The award supports research focused on augmenting the in vivo efficacy of a novel lanosterol synthase inhibitor in glioblastoma treatment. This research aligns with the DHA's mission to transform healthcare for service...
- Federal Grant Award Summary Award Details: The Sloan-Kettering Institute for Cancer Research received a $1.39M Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) on September 1, 2025, with performance extending through August 31, 2029. The award supports an integrated immunomodulatory analysis of LAG3 (Lymphocyte-Activation Gene 3) inhibition in renal cell carcinoma (RCC), a hypothesis-driven research initiative addressing...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded Sloan-Kettering Institute For Cancer Research a $533,308 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2029. The award funds research titled "Integrated Immunomodulatory Analysis of LAG3 Inhibition in Renal Cell Carcinoma," which investigates lymphocyte-activation gene 3 (LAG3) checkpoint inhibition as a therapeutic...
- Federal Grant Award Summary The Sloan-Kettering Institute for Cancer Research received a $176,000 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period September 1, 2025, through August 31, 2026. This award supports research investigating the interactions of mitochondrially encoded Complex I mutations with hypoxia and antitumor immune response in chromophobe renal cell carcinoma. The research aims to advance...
- Federal Project Grant Award Summary The Sloan-Kettering Institute for Cancer Research received a $924,000 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period June 1, 2025 through May 31, 2028. The award supports research on "Therapeutic Strategies for Targeting Diverse KRAS Mutations in Lung Cancer," an initiative aligned with the DHA's mission to advance biomedical research addressing critical...
- Federal Grant Award Summary Sloan-Kettering Institute for Cancer Research received a $559,998 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective June 1, 2026 through May 31, 2028. The award funds research on "Therapeutic Targeting of RNA Processing to Enhance Anti-Melanoma Immunotherapy," a hypothesis-driven investigation designed to advance innovative cancer treatment solutions for military...
- Federal Grant Award Summary Award: Systematic Functional Dissection of Cancer Cell States in Lung Tumors Awardee: Sloan-Kettering Institute For Cancer Research Funding Agency: Defense Health Agency (DHA) Federal Grant Program: Military Medical Research and Development (CFDA 12.420) Award Amount: $923,805.00 Performance Period: September 1, 2025 – August 31, 2028 The Sloan-Kettering Institute for Cancer Research will conduct advanced cancer research focused on systematically analyzing...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $176,000 under the Military Medical Research and Development program (CFDA 12.420) to the Sloan-Kettering Institute for Cancer Research to establish a mouse model of myxoid/round cell liposarcoma with endogenous translocations. The award, effective September 1, 2025, through August 31, 2027, funds basic research aimed at advancing understanding of this rare soft tissue sarcoma through the development of a preclinical...
- Federal Project Grant Award Summary The Sloan-Kettering Institute for Cancer Research received a $176,000 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective November 1, 2025, through October 31, 2027. The award funds research exploring a novel antibody-drug conjugate (ADC) strategy designed to block MYC protein production in neuroblastoma (NB), a pediatric cancer of the nervous system. This research...